Occudo Quantitative Strategies LP Black Diamond Therapeutics, Inc. Transaction History

Occudo Quantitative Strategies LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.67 - $5.74 $18,962 - $40,765	-7,102 Reduced 39.16%	11,032 $55,000
Q4 2023 Feb 14, 2024	SELL	$1.77 - $3.03 $15,271 - $26,142	-8,628 Reduced 32.24%	18,134 $50,000
Q3 2023 Nov 14, 2023	BUY	$2.87 - $4.99 $76,806 - $133,542	26,762 New	26,762 $76,000
Q3 2022 Nov 14, 2022	SELL	$1.68 - $4.01 $1,752 - $4,182	-1,043 Reduced 5.27%	18,764 $32,000
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.63 $10,974 - $26,557	-7,316 Reduced 26.97%	19,807 $49,000
Q1 2022 May 16, 2022	SELL	$2.66 - $5.61 $51,345 - $108,289	-19,303 Reduced 41.58%	27,123 $75,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $8.48 $37,005 - $60,581	7,144 Added 18.19%	46,426 $247,000
Q3 2021 Nov 15, 2021	SELL	$8.46 - $12.42 $559,324 - $821,135	-66,114 Reduced 62.73%	39,282 $332,000
Q2 2021 Aug 16, 2021	BUY	$12.19 - $28.17 $1.28 Million - $2.97 Million	105,396 New	105,396 $1.29 Million
Q1 2021 May 14, 2021	SELL	$22.23 - $34.75 $232,659 - $363,693	-10,466 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.47 - $35.0 $308,433 - $366,310	10,466 New	10,466 $335,000

117

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $80.7M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.